All-trans retinoic acid downregulates ALDH1-mediated stemness and inhibits tumour formation in ovarian cancer cells

Carcinogenesis

Volumn 36, Issue 4, 2014, Pages 498-507

  Young, Ming Jer ^a   Wu, Yi Hui ^a   Chiu, Wen Tai ^b   Weng, Tzu Yu ^a   Huang, Yu Fang ^a   Chou, Cheng Yang ^b  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE ISOENZYME 1; BIOLOGICAL MARKER; NOTCH1 RECEPTOR; PROTEIN FOXM1; RETINOIC ACID; THIOSTREPTON; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DIPEPTIDE; FORKHEAD TRANSCRIPTION FACTOR; FOXM1 PROTEIN, HUMAN; ISOENZYME; N-(N-(3,5-DIFLUOROPHENACETYL)ALANYL)PHENYLGLYCINE TERT-BUTYL ESTER; NOTCH1 PROTEIN, HUMAN; RETINAL DEHYDROGENASE; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER STEM CELL; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; OVARIAN CANCER CELL LINE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR INVASION; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CANCER TRANSPLANTATION; CELL MOTION; CELL TRANSFORMATION; DRUG EFFECTS; GENETICS; MULTICELLULAR SPHEROID; NONOBESE DIABETIC MOUSE; OVARIAN NEOPLASMS; PATHOLOGY; RNA INTERFERENCE; SCID MOUSE; TUMOR CELL CULTURE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL MOVEMENT; CELL TRANSFORMATION, NEOPLASTIC; DIPEPTIDES; DOWN-REGULATION; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; ISOENZYMES; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; OVARIAN NEOPLASMS; RECEPTOR, NOTCH1; RETINAL DEHYDROGENASE; RNA INTERFERENCE; RNA, SMALL INTERFERING; SPHEROIDS, CELLULAR; THIOSTREPTON; TRANSPLANTATION, HETEROLOGOUS; TRETINOIN; TUMOR CELLS, CULTURED;

EID: 84927644916     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgv018     Document Type: Article

References (50)

1. Siegel, R. et al. (2012) Cancer statistics, 2012. CA Cancer J. Clin., 62, 10-29.
2. Huang, Y.F. et al. (2014) Circulating IGF system and treatment outcome in epithelial ovarian cancer. Endocr. Relat. Cancer, 21, 217-229.
3. Cho, K.R. et al. (2009) Ovarian cancer. Annu. Rev. Pathol., 4, 287-313.
4. Zhang, S. et al. (2008) Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res., 68, 4311-4320.
5. Sullivan, J.P. et al. (2010) Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. Cancer Res., 70, 9937-9948.
6. Jiang, L.Y. et al. (2011) γ-Secretase Inhibitor, DAPT Inhibits Self-renewal and Stemness Maintenance of Ovarian Cancer Stem-like Cells In Vitro. Chin. J. Cancer Res., 23, 140-146.
7. Pannuti, A. et al. (2010) Targeting Notch to target cancer stem cells. Clin. Cancer Res., 16, 3141-3152.
8. Ginestier, C. et al. (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell, 1, 555-567.
9. Huang, E.H. et al. (2009) Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res., 69, 3382-3389.
10. Carpentino, J.E. et al. (2009) Aldehyde dehydrogenase-expressing colon stem cells contribute to tumorigenesis in the transition from colitis to cancer. Cancer Res., 69, 8208-8215.
11. Sun, S. et al. (2010) ALDH high adenoid cystic carcinoma cells display cancer stem cell properties and are responsible for mediating metastasis. Biochem. Biophys. Res. Commun., 396, 843-848.
12. van den Hoogen, C. et al. (2010) High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer. Cancer Res., 70, 5163-5173.
13. Han, X. et al. (2013) A2780 human ovarian cancer cells with acquired paclitaxel resistance display cancer stem cell properties. Oncol. Lett., 6, 1295-1298.
14. Liebscher, C.A. et al. (2013) Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma. Hum. Pathol., 44, 1465-1471.
15. Wang, Y.C. et al. (2012) ALDH1-bright epithelial ovarian cancer cells are associated with CD44 expression, drug resistance, and poor clinical outcome. Am. J. Pathol., 180, 1159-1169.
16. Deng, S. et al. (2010) Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS One, 5, e10277.
17. Kuroda, T. et al. (2013) ALDH1-high ovarian cancer stem-like cells can be isolated from serous and clear cell adenocarcinoma cells, and ALDH1 high expression is associated with poor prognosis. PLoS One, 8, e65158.
18. Chang, B. et al. (2009) ALDH1 expression correlates with favorable prognosis in ovarian cancers. Mod. Pathol., 22, 817-823.
19. Liu, S. et al. (2013) Prognostic value of cancer stem cell marker aldehyde dehydrogenase in ovarian cancer: a meta-analysis. PLoS One, 8, e81050.
20. Aguilar-Gallardo, C. et al. (2012) Overcoming challenges of ovarian cancer stem cells: novel therapeutic approaches. Stem Cell Rev., 8, 994-1010.
21. De Maria, R. et al. (2011) Therapeutic Targeting of Cancer Stem Cells. Front Oncol. 17, 1-10.
22. Xu, W.P. et al. (2014) Differentiation therapy for solid tumors. J. Dig. Dis., 15, 159-165.
23. Shi, Z. et al. (2013) Effect of all-trans retinoic acid on the differentiation of U87 glioma stem/progenitor cells. Cell. Mol. Neurobiol., 33, 943-951.
24. Campos, B. et al. (2010) Differentiation therapy exerts antitumor effects on stem-like glioma cells. Clin. Cancer Res., 16, 2715-2728.
25. Lim, Y.C. et al. (2012) All-trans-retinoic acid inhibits growth of head and neck cancer stem cells by suppression of Wnt/β-catenin pathway. Eur. J. Cancer, 48, 3310-3318.
26. Ginestier, C. et al. (2009) Retinoid signaling regulates breast cancer stem cell differentiation. Cell Cycle, 8, 3297-3302.
27. Whitworth, J.M. et al. (2012) The impact of novel retinoids in combination with platinum chemotherapy on ovarian cancer stem cells. Gynecol. Oncol., 125, 226-230.
28. Hong, G.Y. et al. (2011) Combination of paclitaxel-and retinoic acidincorporated nanoparticles for the treatment of CT-26 colon carcinoma. Arch. Pharm. Res., 34, 407-417.
29. Narvekar, M. et al. (2014) A new nanostructured carrier design including oil to enhance the pharmaceutical properties of retinoid therapy and its therapeutic effects on chemo-resistant ovarian cancer. Eur. J. Pharm. Biopharm., 88, 226-237.
30. Elizondo, G. et al. (2009) Retinoic acid modulates retinaldehyde dehydrogenase 1 gene expression through the induction of GADD153-C/EBPbeta interaction. Biochem. Pharmacol., 77, 248-257.
31. Moreb, J.S. et al. (2005) Retinoic acid down-regulates aldehyde dehydrogenase and increases cytotoxicity of 4-hydroperoxycyclophosphamide and acetaldehyde. J. Pharmacol. Exp. Ther., 312, 339-345.
32. Molthoff, C.F. et al. (1991) Human ovarian cancer xenografts in nude mice: characterization and analysis of antigen expression. Int. J. Cancer, 47, 72-79.
33. Saw, Y.T. et al. (2012) Characterization of aldehyde dehydrogenase isozymes in ovarian cancer tissues and sphere cultures. BMC Cancer, 12, 329.
34. Bell, D. et al. (2011) Integrated genomic analyses of ovarian carcinoma. Nature. 474, 609-615.33.
35. Kryczek, I. et al. (2012) Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells. Int. J. Cancer, 130, 29-39.
36. Zhan, Q. et al. (2013) Ovarian cancer stem cells: a new target for cancer therapy. Biomed Res. Int., 2013, 916819.
37. Landen, C.N. Jr et al. (2010) Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol. Cancer Ther., 9, 3186-3199.
38. Wang, Z. et al. (2010) Forkhead box M1 transcription factor: a novel target for cancer therapy. Cancer Treat. Rev., 36, 151-156.
39. Koo, C.Y. et al. (2012) FOXM1: from cancer initiation to progression and treatment. Biochim. Biophys. Acta, 1819, 28-37.
40. Pilarsky, C. et al. (2004) Identification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data. Neoplasia, 6, 744-750.
41. Uddin, S. et al. (2011) Genome-wide expression analysis of Middle Eastern colorectal cancer reveals FOXM1 as a novel target for cancer therapy. Am. J. Pathol., 178, 537-547.
42. Wang, Y. et al. (2013) FoxM1 expression is significantly associated with cisplatin-based chemotherapy resistance and poor prognosis in advanced non-small cell lung cancer patients. Lung Cancer, 79, 173-179.
43. Gemenetzidis, E. et al. (2010) Induction of human epithelial stem/progenitor expansion by FOXM1. Cancer Res., 70, 9515-9526.
44. Xie, Z. et al. (2010) Foxm1 transcription factor is required for maintenance of pluripotency of P19 embryonal carcinoma cells. Nucleic Acids Res., 38, 8027-8038.
45. Gong, A, et al. (2012) FoxM1 and Wnt/beta-catenin signaling in glioma stem cells. Cancer Res. 72,5658-5662.
46. Wang, Z. et al. (2011) Down-regulation of Notch-1 is associated with Akt and FoxM1 in inducing cell growth inhibition and apoptosis in prostate cancer cells. J. Cell. Biochem., 112, 78-88.
47. Ma, I. et al. (2011) The role of human aldehyde dehydrogenase in normal and cancer stem cells. Stem Cell Rev., 7, 292-306.
48. Tang, X.H. et al. (2011) Retinoids, retinoic acid receptors, and cancer. Annu. Rev. Pathol., 6, 345-364.
49. Masetti, R. et al. (2012) All-trans retinoic acid in the treatment of pediatric acute promyelocytic leukemia. Expert Rev. Anticancer Ther., 12, 1191-1204.
50. U.S. National Institutes of Health service. Use ClinicalTrials.gov search features to find studies: ATRA and cancer. https://clinicaltrials.gov/ct2/results?term=atra+cancer&Search=Search (23 March 2015, date last accessed).